The neuroprotective effect of the novel noncompetitive NMDA antagonist, FR115427 in focal cerebral ischemia in rats.

Abstract

The present study was carried out to compare the neuroprotective effect of the novel noncompetitive NMDA antagonist, FR115427, with that of(+)MK-801 in rat focal cerebral ischemia. Focal cerebral ischemia was produced by permanent occlusion of the left middle cerebral artery (MCA). Drugs were administered intraperitoneally immediately after ischemia and once a day for 6 successive days. FR115427 (10 mg/kg, i.p.) significantly improved neurologic deficit at 1 day after ischemia and reduced total infarct volume (54%) at 7 days after ischemia. Although FR115427 (10 mg/kg, s.c.) produced neuronal vacuolization similar to (+)MK-801, FR115427 did not produce adverse effects such as a loss of body weight, mortality, and hypothermia, in contrast to (+)MK-801. These results suggest that FR115427 may be useful in the treatment of stroke.

• Authors: K Katsuta, H Nakanishi, K Shirakawa, K Yoshida, K Takagi, A Tamura
• Journal: Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism (J Cereb Blood Flow Metab) Vol. 15 Issue 2 Pg. 345-8 (Mar 1995) ISSN: 0271-678X [Print] United States
• PMID: 7860668 (Publication Type: Comparative Study, Journal Article)

Chemical References

• Isoquinolines
• Neuroprotective Agents
• Receptors, N-Methyl-D-Aspartate
• Tetrahydroisoquinolines
• 1-methyl-1-phenyl-1,2,3,4-tetrahydroisoquinoline
• Dizocilpine Maleate

Topics

• Animals
• Brain Diseases (etiology, prevention & control)
• Brain Ischemia (complications, drug therapy)
• Dizocilpine Maleate (therapeutic use)
• Isoquinolines (therapeutic use)
• Male
• Neuroprotective Agents (therapeutic use)
• Rats
• Rats, Sprague-Dawley
• Receptors, N-Methyl-D-Aspartate (antagonists & inhibitors)
• Tetrahydroisoquinolines